Developer docs
API playgroundTry for free, no card

Search company profiles

Nacuity Pharmaceuticals

Full company profile

uuid000245e

Namestring
Nacuity Pharmaceuticals
Legal namestring
Nacuity Pharmaceuticals, Inc.
Websiteurl
nacuity.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Nacuity Pharmaceuticals is a clinical-stage private biopharmaceutical company founded in 2017 and headquartered in Fort Worth, Texas, that develops targeted antioxidant therapies to stop oxidative tissue damage in rare blinding eye diseases and related chronic conditions. The company's proprietary technology platform centers on two small molecules licensed from Johns Hopkins University: NPI-001 (N-acetylcysteine amide, or NACA), a GMP-grade oral tablet that donates cysteine to boost intracellular glutathione biosynthesis and crosses the blood-brain and blood-retinal barriers with approximately three-fold greater efficacy than standard N-acetylcysteine; and NPI-002 (diNACA), a sustained-release intravitreal implant co-developed with Integral Biosystems using its NanoM delivery platform. The company runs five development programs (NP-1 through NP-5) covering retinitis pigmentosa associated with Usher syndrome, cataract progression post-vitrectomy, nephropathic cystinosis, AMD and Stargardt disease, and Hereditary Cystatin C Amyloid Angiopathy (HCCAA), with three Phase 1/2 trials active across Australian clinical sites.

Nacuity's go-to-market motion is entirely clinical-trial-driven at present, with patient access to investigational products limited to trial participation. The lead NPI-001 RP program received FDA Orphan Drug, Fast Track (January 2025), and Breakthrough Therapy Designations (October 2025), and produced Phase 1/2 data in September 2025 demonstrating more than 50% reduction in photoreceptor loss over two years versus placebo. Manufacturing readiness is being built through a $3.2M API contract with IDT Australia and a collaboration with Integral Biosystems for sustained-release implant technology, while Arctic Therapeutics holds exclusive rights to develop NPI-001 (as AT-001) for HCCAA in Iceland and related cerebral amyloid angiopathies worldwide under an EMA-approved protocol. The company is venture-backed by Foundation Fighting Blindness and its RD Fund (which co-led a $16.5M Series B in June 2022), with Johns Hopkins University holding equity from the 2018 IP license; the management team and Scientific Advisory Board draw heavily from former Alcon Laboratories leadership and Johns Hopkins Wilmer Eye Institute faculty. All products remain investigational, no commercial pricing exists, and the company is pre-revenue.

Short descriptiontext

Nacuity Pharmaceuticals is a clinical-stage private biopharma developing NACA-based antioxidant therapies (oral tablets and intravitreal implants) for rare ocular diseases including retinitis pigmentosa, cataract, and cystinosis, currently operating through Phase 1/2 trials with no approved products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFort Worth, United States
HQ citystring
Fort Worth
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oxidative stress therapeutics, retinitis pigmentosa treatment, ophthalmic drug development, antioxidant pharmaceuticals, rare disease therapies
Industry3 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals for Rare Eye Diseases
Social media profiles1 record
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nacuity Pharmaceuticals develops prescription-grade antioxidant therapeutics that target oxidative stress to treat rare blinding eye diseases and serious chronic conditions. The company's lead clinical assets are NPI-001 (N-acetylcysteine amide oral tablets) for retinitis pigmentosa, nephropathic cystinosis, and Hereditary Cystatin C Amyloid Angiopathy, and NPI-002 (a sustained-release intravitreal implant of diNACA) for delaying cataract progression. Five development programs (NP-1 through NP-5) are progressing through Phase 1/2 clinical trials under FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • NPI-001 slowed photoreceptor loss by more than 50% over two years in RP associated with Usher syndrome vs. placebo (Phase 1/2 SLO-RP trial, September 2025 data)
+4 more records
Product overview1 text field

Nacuity Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted antioxidant therapies to stop oxidative tissue damage. The company's product portfolio consists of two lead product candidates: NPI-001 (N-acetylcysteine amide) tablets, an oral formulation for retinitis pigmentosa, cystinosis, and rare neurological diseases; and NPI-002, a sustained-release intravitreal implant for cataract progression. Both products leverage the company's proprietary antioxidant technology platform targeting oxidative stress, with five development programs (NP-1 through NP-5) addressing conditions including retinitis pigmentosa, cataract, nephropathic cystinosis, AMD, Stargardt disease, and HCCAA.

Product and service7 records
1NPI-001 (N-acetylcysteine amide) Tablets
CategoryInvestigational oral antioxidant drug product
Description

Proprietary GMP-grade oral tablet formulation of N-acetylcysteine amide (NACA) designed to boost intracellular glutathione biosynthesis and stop oxidative tissue damage in patients with blinding eye diseases including retinitis pigmentosa and nephropathic cystinosis, as well as rare neurological conditions such as Hereditary Cystatin C Amyloid Angiopathy.

2NPI-002 Intravitreal Implant
CategoryInvestigational sustained-release ophthalmic implant
Description

Novel sustained-release sterile intravitreal implant delivering diNACA (di-N-acetylcysteine amide) via a precision delivery system with vitreal elution over time. Designed to inhibit oxidative-induced cataract formation in patients undergoing vitrectomy.

3NP-1 Program (Oral NPI-001 for Retinitis Pigmentosa)
CategoryInvestigational oral therapy program for retinitis pigmentosa
Description

Development program for an oral small molecule therapy targeting oxidative stress to slow or halt disease progression in retinitis pigmentosa patients with functioning cones, regardless of the underlying genetic mutation.

4NP-2 Program (NPI-002 Implant for Cataract Progression)
CategoryInvestigational ophthalmic implant program for cataract
Description

Development program for a sustained-release intravitreal implant delivering a slow-release antioxidant molecule to slow cataract progression in patients undergoing vitrectomy.

5NP-3 Program (Oral NPI-001 for Nephropathic Cystinosis)
CategoryInvestigational oral therapy program for nephropathic cystinosis
Description

Development program investigating NPI-001 oral therapy as a disease-modifying antioxidant treatment for nephropathic cystinosis, with potential for improved compliance over existing unpalatable cysteamine therapies.

6NP-4 Program (Intravitreal Implant for AMD and Stargardt Disease)
CategoryInvestigational ophthalmic therapy program for AMD and Stargardt disease
Description

Development program evaluating intravitreal delivery of NPI-001 or NPI-002 as potential treatments for retinal degenerative diseases including age-related macular degeneration and Stargardt disease.

7NP-5 Program (Oral NPI-001 for Hereditary Cystatin C Amyloid Angiopathy)
CategoryInvestigational oral therapy program for HCCAA (rare neurological disease)
Description

Development program (licensed to Arctic Therapeutics as AT-001) evaluating oral NPI-001 for treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare neurological disease prevalent in Icelanders, leveraging NPI-001's ability to cross the blood-brain barrier.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-04-09
Description

IDT Australia secured a manufacturing contract with Nacuity Pharmaceuticals Pty Ltd for NPI-001, an investigational treatment for retinitis pigmentosa (RP). This $3.2M contract supports recomissioning of Australia's largest small molecule API plant.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-09-13
Description

Exclusive licensing agreement and strategic partnership for development and commercialization of NPI-001 (as AT-001) for Hereditary Cystatin C Amyloid Angiopathy (HCCAA) in Iceland and related CAAs worldwide. Nacuity provides exclusive rights to Arctic for HCCAA in Iceland; Nacuity and Arctic collaborate on all regulatory approval and development activities. In March 2024, EMA approved the first clinical trial of AT-001 for HCCAA in Iceland.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-08-13
Description

Collaboration and License Agreement signed August 2021 to co-develop sustained release products utilizing Nacuity's proprietary antioxidant compounds and Integral's patented NanoM platform ophthalmic insert technology. The collaboration targets several ocular disorders including development of the NPI-002 intravitreal implant for cataract.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-03-31
Description

Technology Proof of Concept (PoC) Agreement signed March 2021 to apply Nanoform's award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity's NPI-001 and NPI-002 drug candidates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-13
Description

Exclusive worldwide license from Johns Hopkins University to IP underlying patent applications covering treatment of RP with N-acetylcysteine amide and biomarkers. Nacuity previously held non-exclusive rights before upgrading to exclusive license. JHU became a shareholder and is entitled to milestone payments and royalties on clinical development and regulatory approval. The license builds on research from Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina.

Strategic tierSupportingTypeOthers
Description

Industrial collaborator providing clinical research services. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Contract research organization specializing in topical and ophthalmic formulations. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Contract research organization providing drug discovery services. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Medical device and imaging company providing spectral-domain optical coherence tomography (SD-OCT) technology for clinical trials. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Australian-based contract research organization conducting clinical trials. Supports Nacuity's clinical trial operations in Australia.

Strategic tierSupportingTypeOthers
Description

Pharmaceutical contract manufacturing and supply chain services. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Business and regulatory consulting firm supporting Nacuity's operations. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Contract manufacturing organization. Listed as an industrial collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Academic research institution collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.

Strategic tierSupportingTypeOthers
Description

Academic research institution with North Texas Eye Research Institute collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.

16Howard Hughes Medical Institute
Strategic tierSupportingTypeOthers
Description

Medical research institute supporting Nacuity's research. Listed on the Investors & Collaborators page under Academic Research.

nacuity.com
Strategic tierSupportingTypeOthers
Description

Academic institution collaborating with Nacuity on research. Listed on the Investors & Collaborators page under Academic Research.

Strategic tierSupportingTypeOthers
Description

Academic institution (Dunaieff Lab) collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.

19The Florey Institute of Neuroscience & Mental Health
Strategic tierSupportingTypeOthers
Description

Australian neuroscience research institute collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.

nacuity.com
Strategic tierSupportingTypeOthers
Description

Baylor College of Medicine's Cullen Eye Institute, where board member Tim Stout, MD, PhD, MBA serves as Director. Listed as an academic research collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Australian academic institution where Nacuity's cataract clinical trial (NP-2) is conducted. Listed as an academic research collaborator on the Investors & Collaborators page.

Strategic tierSupportingTypeOthers
Description

Provider of imaging analysis for Nacuity's clinical trials. Listed as an academic research collaborator on the Investors & Collaborators page.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty pharmaceutical company with a dedicated rare disease business including ophthalmology and metabolic disorders. Relevant as a potential commercial partner or acquirer for Nacuity's cystinosis and ophthalmology programs given its established rare disease commercial infrastructure.

TypeDirect peer
Description

Clinical-stage ophthalmology company specializing in suprachoroidal drug delivery for retinal diseases. Shares a Scientific Advisory Board member (Gerald Cagle) with Nacuity and competes in the ocular drug delivery space, particularly relevant to Nacuity's NPI-002 intravitreal implant.

TypeBroad incumbent
Description

Global leader in ophthalmic pharmaceuticals, surgical equipment, and vision care. Multiple Nacuity founders and senior leaders (CEO Halden Conner, CSO Michael Wall, board members Gerald Cagle and Onkar Singh) are former Alcon executives, illustrating the deep domain overlap and the company Alcon represents as a potential strategic acquirer or commercial partner.

TypeDirect peer
Description

Clinical-stage cell therapy company developing jCell, a stem-cell-based treatment for retinitis pigmentosa. Directly competes with Nacuity in the RP indication through a cell-replacement approach versus Nacuity's antioxidant mechanism.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on inherited retinal diseases including retinitis pigmentosa. Shares the same Foundation Fighting Blindness / RD Fund investor backing and Scientific Advisory Board leadership as Nacuity, and competes for the same patient population with a mutation-specific gene therapy approach versus Nacuity's gene-agnostic small molecule.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including X-linked retinitis pigmentosa. Direct competitor in the RP indication through a different therapeutic modality.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including Leber congenital amaurosis and retinitis pigmentosa. Russell Kelley (RD Fund, Nacuity board) is listed as a board observer, indicating shared investor ecosystem and overlapping indication strategy.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company developing Axiomer RNA editing therapies for inherited retinal diseases including Usher syndrome and retinitis pigmentosa. Targets the same RP/Usher syndrome population as Nacuity's lead NPI-001 program through a different (RNA-based) modality.

TypeEmerging player
Description

Clinical-stage gene-editing company developing in vivo CRISPR-based therapies for inherited retinal diseases. Competes in the broader retinal disease space with a transformative modality that could complement or substitute for Nacuity's antioxidant approach.

10SparingVision
TypeDirect peer
Description

Clinical-stage ophthalmology company developing gene therapies for retinitis pigmentosa and other inherited retinal diseases. Directly competes with Nacuity's lead NPI-001 program in the same RP indication, addressing oxidative-stress-related photoreceptor loss through a different (gene therapy) modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles22 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nacuity Pharmaceuticals

Ophthalmic Pharmaceuticals for Rare Eye Diseasesnacuity.com

Nacuity Pharmaceuticals is a clinical-stage private biopharma developing NACA-based antioxidant therapies (oral tablets and intravitreal implants) for rare ocular diseases including retinitis pigmentosa, cataract, and cystinosis, currently operating through Phase 1/2 trials with no approved products.

What Nacuity Pharmaceuticals does

Nacuity Pharmaceuticals is a clinical-stage private biopharmaceutical company founded in 2017 and headquartered in Fort Worth, Texas, that develops targeted antioxidant therapies to stop oxidative tissue damage in rare blinding eye diseases and related chronic conditions. The company's proprietary technology platform centers on two small molecules licensed from Johns Hopkins University: NPI-001 (N-acetylcysteine amide, or NACA), a GMP-grade oral tablet that donates cysteine to boost intracellular glutathione biosynthesis and crosses the blood-brain and blood-retinal barriers with approximately three-fold greater efficacy than standard N-acetylcysteine; and NPI-002 (diNACA), a sustained-release intravitreal implant co-developed with Integral Biosystems using its NanoM delivery platform. The company runs five development programs (NP-1 through NP-5) covering retinitis pigmentosa associated with Usher syndrome, cataract progression post-vitrectomy, nephropathic cystinosis, AMD and Stargardt disease, and Hereditary Cystatin C Amyloid Angiopathy (HCCAA), with three Phase 1/2 trials active across Australian clinical sites.

Nacuity's go-to-market motion is entirely clinical-trial-driven at present, with patient access to investigational products limited to trial participation. The lead NPI-001 RP program received FDA Orphan Drug, Fast Track (January 2025), and Breakthrough Therapy Designations (October 2025), and produced Phase 1/2 data in September 2025 demonstrating more than 50% reduction in photoreceptor loss over two years versus placebo. Manufacturing readiness is being built through a $3.2M API contract with IDT Australia and a collaboration with Integral Biosystems for sustained-release implant technology, while Arctic Therapeutics holds exclusive rights to develop NPI-001 (as AT-001) for HCCAA in Iceland and related cerebral amyloid angiopathies worldwide under an EMA-approved protocol. The company is venture-backed by Foundation Fighting Blindness and its RD Fund (which co-led a $16.5M Series B in June 2022), with Johns Hopkins University holding equity from the 2018 IP license; the management team and Scientific Advisory Board draw heavily from former Alcon Laboratories leadership and Johns Hopkins Wilmer Eye Institute faculty. All products remain investigational, no commercial pricing exists, and the company is pre-revenue.

Nacuity Pharmaceuticals firmographics

Firmographics
Name
Nacuity Pharmaceuticals
Legal name
Nacuity Pharmaceuticals, Inc.
Website
https://nacuity.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Nacuity Pharmaceuticals is a clinical-stage private biopharma developing NACA-based antioxidant therapies (oral tablets and intravitreal implants) for rare ocular diseases including retinitis pigmentosa, cataract, and cystinosis, currently operating through Phase 1/2 trials with no approved products.
Ownership category
akta.pro rank

Nacuity Pharmaceuticals industry classification

Industry
Product category
Ophthalmic Pharmaceuticals for Rare Eye Diseases
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Oxidative stress therapeutics
  • Retinitis pigmentosa treatment
  • Ophthalmic drug development
  • Antioxidant pharmaceuticals
  • Rare disease therapies

Where Nacuity Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Fort Worth
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nacuity Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Distribution channels3 records

Marketing channels5 records

Nacuity Pharmaceuticals product offering

Product offering

Core offering

Nacuity Pharmaceuticals develops prescription-grade antioxidant therapeutics that target oxidative stress to treat rare blinding eye diseases and serious chronic conditions. The company's lead clinical assets are NPI-001 (N-acetylcysteine amide oral tablets) for retinitis pigmentosa, nephropathic cystinosis, and Hereditary Cystatin C Amyloid Angiopathy, and NPI-002 (a sustained-release intravitreal implant of diNACA) for delaying cataract progression. Five development programs (NP-1 through NP-5) are progressing through Phase 1/2 clinical trials under FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations.

Product overview

Nacuity Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted antioxidant therapies to stop oxidative tissue damage. The company's product portfolio consists of two lead product candidates: NPI-001 (N-acetylcysteine amide) tablets, an oral formulation for retinitis pigmentosa, cystinosis, and rare neurological diseases; and NPI-002, a sustained-release intravitreal implant for cataract progression. Both products leverage the company's proprietary antioxidant technology platform targeting oxidative stress, with five development programs (NP-1 through NP-5) addressing conditions including retinitis pigmentosa, cataract, nephropathic cystinosis, AMD, Stargardt disease, and HCCAA.

Differentiator

Problem solved

Functional benefit

Products and services

  • NPI-001 (N-acetylcysteine amide) Tablets Proprietary GMP-grade oral tablet formulation of N-acetylcysteine amide (NACA) designed to boost intracellular glutathione biosynthesis and stop oxidative tissue damage in patients with blinding eye diseases including retinitis pigmentosa and nephropathic cystinosis, as well as rare neurological conditions such as Hereditary Cystatin C Amyloid Angiopathy.
  • NPI-002 Intravitreal Implant Novel sustained-release sterile intravitreal implant delivering diNACA (di-N-acetylcysteine amide) via a precision delivery system with vitreal elution over time. Designed to inhibit oxidative-induced cataract formation in patients undergoing vitrectomy.
  • NP-1 Program (Oral NPI-001 for Retinitis Pigmentosa) Development program for an oral small molecule therapy targeting oxidative stress to slow or halt disease progression in retinitis pigmentosa patients with functioning cones, regardless of the underlying genetic mutation.
  • NP-2 Program (NPI-002 Implant for Cataract Progression) Development program for a sustained-release intravitreal implant delivering a slow-release antioxidant molecule to slow cataract progression in patients undergoing vitrectomy.
  • NP-3 Program (Oral NPI-001 for Nephropathic Cystinosis) Development program investigating NPI-001 oral therapy as a disease-modifying antioxidant treatment for nephropathic cystinosis, with potential for improved compliance over existing unpalatable cysteamine therapies.
  • NP-4 Program (Intravitreal Implant for AMD and Stargardt Disease) Development program evaluating intravitreal delivery of NPI-001 or NPI-002 as potential treatments for retinal degenerative diseases including age-related macular degeneration and Stargardt disease.
  • NP-5 Program (Oral NPI-001 for Hereditary Cystatin C Amyloid Angiopathy) Development program (licensed to Arctic Therapeutics as AT-001) evaluating oral NPI-001 for treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare neurological disease prevalent in Icelanders, leveraging NPI-001's ability to cross the blood-brain barrier.

Quantifiable outcome

  • NPI-001 slowed photoreceptor loss by more than 50% over two years in RP associated with Usher syndrome vs. placebo (Phase 1/2 SLO-RP trial, September 2025 data)
  • +4 more outcomes

Companies that use Nacuity Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Nacuity Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nacuity Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered supporting, flagship and core.

  • IDT Australia LimitedsupportingTechnology or Integration · 9 April 2025IDT Australia secured a manufacturing contract with Nacuity Pharmaceuticals Pty Ltd for NPI-001, an investigational treatment for retinitis pigmentosa (RP). This $3.2M contract supports recomissioning of Australia's largest small molecule API plant.
  • Arctic TherapeuticsflagshipStrategic or Co-development Partner · 13 September 2022Exclusive licensing agreement and strategic partnership for development and commercialization of NPI-001 (as AT-001) for Hereditary Cystatin C Amyloid Angiopathy (HCCAA) in Iceland and related CAAs worldwide. Nacuity provides exclusive rights to Arctic for HCCAA in Iceland; Nacuity and Arctic collaborate on all regulatory approval and development activities. In March 2024, EMA approved the first clinical trial of AT-001 for HCCAA in Iceland.
  • Integral BiosystemscoreTechnology or Integration · 13 August 2021Collaboration and License Agreement signed August 2021 to co-develop sustained release products utilizing Nacuity's proprietary antioxidant compounds and Integral's patented NanoM platform ophthalmic insert technology. The collaboration targets several ocular disorders including development of the NPI-002 intravitreal implant for cataract.
  • Nanoform Finland PlcsupportingTechnology or Integration · 31 March 2021Technology Proof of Concept (PoC) Agreement signed March 2021 to apply Nanoform's award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity's NPI-001 and NPI-002 drug candidates.
  • Johns Hopkins University (Wilmer Eye Institute)coreStrategic or Co-development Partner · 13 June 2018Exclusive worldwide license from Johns Hopkins University to IP underlying patent applications covering treatment of RP with N-acetylcysteine amide and biomarkers. Nacuity previously held non-exclusive rights before upgrading to exclusive license. JHU became a shareholder and is entitled to milestone payments and royalties on clinical development and regulatory approval. The license builds on research from Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina.
  • Statistics Data CorporationsupportingOthersIndustrial collaborator providing clinical research services. Listed as an industrial collaborator on the Investors & Collaborators page.
  • MedPharmsupportingOthersContract research organization specializing in topical and ophthalmic formulations. Listed as an industrial collaborator on the Investors & Collaborators page.
  • Eurofins DiscoverysupportingOthersContract research organization providing drug discovery services. Listed as an industrial collaborator on the Investors & Collaborators page.
  • Heidelberg EngineeringsupportingOthersMedical device and imaging company providing spectral-domain optical coherence tomography (SD-OCT) technology for clinical trials. Listed as an industrial collaborator on the Investors & Collaborators page.
  • CMAX Clinical Trials and ResearchsupportingOthersAustralian-based contract research organization conducting clinical trials. Supports Nacuity's clinical trial operations in Australia.
  • PCI Pharma ServicessupportingOthersPharmaceutical contract manufacturing and supply chain services. Listed as an industrial collaborator on the Investors & Collaborators page.
  • AcclimesupportingOthersBusiness and regulatory consulting firm supporting Nacuity's operations. Listed as an industrial collaborator on the Investors & Collaborators page.
  • BDG SynthesissupportingOthersContract manufacturing organization. Listed as an industrial collaborator on the Investors & Collaborators page.
  • University of AucklandsupportingOthersAcademic research institution collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
  • UNT Health Science Center / North Texas Eye Research InstitutesupportingOthersAcademic research institution with North Texas Eye Research Institute collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
  • Howard Hughes Medical InstitutesupportingOthersMedical research institute supporting Nacuity's research. Listed on the Investors & Collaborators page under Academic Research.
  • Robert Gordon University AberdeensupportingOthersAcademic institution collaborating with Nacuity on research. Listed on the Investors & Collaborators page under Academic Research.
  • University of PennsylvaniasupportingOthersAcademic institution (Dunaieff Lab) collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
  • The Florey Institute of Neuroscience & Mental HealthsupportingOthersAustralian neuroscience research institute collaborating with Nacuity. Listed on the Investors & Collaborators page under Academic Research.
  • Baylor College of Medicine (Cullen Eye Institute)supportingOthersBaylor College of Medicine's Cullen Eye Institute, where board member Tim Stout, MD, PhD, MBA serves as Director. Listed as an academic research collaborator on the Investors & Collaborators page.
  • The University of Adelaide Ophthalmic Research LaboratorysupportingOthersAustralian academic institution where Nacuity's cataract clinical trial (NP-2) is conducted. Listed as an academic research collaborator on the Investors & Collaborators page.
  • Doheny Eye InstitutesupportingOthersProvider of imaging analysis for Nacuity's clinical trials. Listed as an academic research collaborator on the Investors & Collaborators page.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Nacuity Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Recordati Rare Diseases: Specialty pharmaceutical company with a dedicated rare disease business including ophthalmology and metabolic disorders. Relevant as a potential commercial partner or acquirer for Nacuity's cystinosis and ophthalmology programs given its established rare disease commercial infrastructure.
  • Alcon: Global leader in ophthalmic pharmaceuticals, surgical equipment, and vision care. Multiple Nacuity founders and senior leaders (CEO Halden Conner, CSO Michael Wall, board members Gerald Cagle and Onkar Singh) are former Alcon executives, illustrating the deep domain overlap and the company Alcon represents as a potential strategic acquirer or commercial partner.

Direct peers

  • Clearside Biomedical: Clinical-stage ophthalmology company specializing in suprachoroidal drug delivery for retinal diseases. Shares a Scientific Advisory Board member (Gerald Cagle) with Nacuity and competes in the ocular drug delivery space, particularly relevant to Nacuity's NPI-002 intravitreal implant.
  • jCyte: Clinical-stage cell therapy company developing jCell, a stem-cell-based treatment for retinitis pigmentosa. Directly competes with Nacuity in the RP indication through a cell-replacement approach versus Nacuity's antioxidant mechanism.
  • Opus Genetics: Clinical-stage gene therapy company focused on inherited retinal diseases including retinitis pigmentosa. Shares the same Foundation Fighting Blindness / RD Fund investor backing and Scientific Advisory Board leadership as Nacuity, and competes for the same patient population with a mutation-specific gene therapy approach versus Nacuity's gene-agnostic small molecule.
  • Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including X-linked retinitis pigmentosa. Direct competitor in the RP indication through a different therapeutic modality.
  • Atsena Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for inherited retinal diseases including Leber congenital amaurosis and retinitis pigmentosa. Russell Kelley (RD Fund, Nacuity board) is listed as a board observer, indicating shared investor ecosystem and overlapping indication strategy.
  • ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer RNA editing therapies for inherited retinal diseases including Usher syndrome and retinitis pigmentosa. Targets the same RP/Usher syndrome population as Nacuity's lead NPI-001 program through a different (RNA-based) modality.
  • SparingVision: Clinical-stage ophthalmology company developing gene therapies for retinitis pigmentosa and other inherited retinal diseases. Directly competes with Nacuity's lead NPI-001 program in the same RP indication, addressing oxidative-stress-related photoreceptor loss through a different (gene therapy) modality.

Emerging players

  • Editas Medicine: Clinical-stage gene-editing company developing in vivo CRISPR-based therapies for inherited retinal diseases. Competes in the broader retinal disease space with a transformative modality that could complement or substitute for Nacuity's antioxidant approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nacuity Pharmaceuticals social profiles

Digital presence

Nacuity Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nacuity Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles22 records

Nacuity Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nacuity Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nacuity Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nacuity Pharmaceuticals

What does Nacuity Pharmaceuticals do?

Nacuity Pharmaceuticals develops prescription-grade antioxidant therapeutics that target oxidative stress to treat rare blinding eye diseases and serious chronic conditions. The company's lead clinical assets are NPI-001 (N-acetylcysteine amide oral tablets) for retinitis pigmentosa, nephropathic cystinosis, and Hereditary Cystatin C Amyloid Angiopathy, and NPI-002 (a sustained-release intravitreal implant of diNACA) for delaying cataract progression. Five development programs (NP-1 through NP-5) are progressing through Phase 1/2 clinical trials under FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations.

Is Nacuity Pharmaceuticals a public or private company?

Nacuity Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nacuity Pharmaceuticals founded?

Nacuity Pharmaceuticals was founded in 2017. It employs 1 to 10 people.

Where is Nacuity Pharmaceuticals based?

Nacuity Pharmaceuticals is headquartered in Fort Worth, United States, in the North America region.

Who are Nacuity Pharmaceuticals's main competitors?

Broad incumbents on record are Recordati Rare Diseases and Alcon. Direct peers are Clearside Biomedical, jCyte, Opus Genetics, Applied Genetic Technologies Corp (AGTC), Atsena Therapeutics, ProQR Therapeutics and SparingVision. Editas Medicine is listed as an emerging player.

Does Nacuity Pharmaceuticals have an API?

No public API is recorded for Nacuity Pharmaceuticals.

What industry is Nacuity Pharmaceuticals in?

Nacuity Pharmaceuticals's product category is Ophthalmic Pharmaceuticals for Rare Eye Diseases. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 339115 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Market Research & Business IntelligenceGlobal X-Linked Retinitis Pigmentosa Market — Analysis of Key Trends, Regional Growth, Top Players, and a 10-year Forecast from 2026 to 2036.Future Market Insights projects the global X-Linked Retinitis Pigmentosa market to grow from USD 348.9 million in 2026 to USD 1,143.1 million by 2036, driven primarily by gene therapy advancements. Key industry participants including Beacon Therapeutics, MeiraGTx, and Nacuity Pharmaceuticals are advancing clinical trials or securing regulatory designations for targeted treatments.Eyes On EyecareFDA grants Breakthrough Therapy Designation to Nacuity's RP tabletsThe FDA has granted Breakthrough Therapy Designation to Nacuity Pharmaceuticals' investigational drug NPI-001 for the treatment of retinitis pigmentosa associated with Usher syndrome. This designation follows positive Phase 1/2 trial results showing that daily dosing slowed photoreceptor loss by over 50% compared to placebo while maintaining a safe and well-tolerated profile. The approval aims to expedite the development and review process for this serious disease, building upon previous Fast Track and Orphan Drug designations.Eyes On EyecareFDA grants Nacuity Pharmaceuticals Fast Track designation for RP tabletsThe FDA has granted Fast Track designation to Nacuity Pharmaceuticals' investigational therapy, NPI-001, for the treatment of retinitis pigmentosa. This regulatory status aims to expedite the development and review process for the drug, which targets oxidative stress associated with the condition. The company previously received Orphan Drug designation for NPI-001 and is currently conducting a phase 1/2 clinical trial for patients with Usher syndrome.GlobeNewswireNacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis PigmentosaNacuity Pharmaceuticals announced the FDA granted Fast Track designation to its NPI-001 tablets for retinitis pigmentosa. The drug also received Orphan Drug Designation, providing seven years of exclusivity. NPI-001 is an antioxidant formulation targeting oxidative stress in the disease.PR NewswireUsher Syndrome Market to Exhibit Growth at a CAGR of 10.55% by 2034 | DelveInsightDelveInsight's Usher Syndrome Market Insights report projects the market will grow at a CAGR of 10.55%, reaching USD 76.48 million in 2023 across the 7MM (United States, EU4, and United Kingdom, and Japan), with the US accounting for the highest prevalent cases at around 21,000 in 2023. Multiple pharmaceutical companies including Laboratoires Théa, Nacuity Pharmaceuticals, AAVantgarde Bio, Odylia Therapeutics, Eli Lilly and Company, Atsena Therapeutics, and Clearside Biomedical are actively developing pipeline therapies such as ULTEVURSEN, NPI-001, and ATSN-301. The FDA previously granted Rare Pediatric Disease designation to QR-421a in January 2020, and emerging gene therapies targeting various Usher syndrome subtypes are expected to drive market growth during the forecast period.GlobeNewswireNacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel FellerNacuity Pharmaceuticals appointed Daniel Feller to its business advisory board. Feller, CEO of Talisman Licensing and COO of GEM42S, co-founded Genetic Cures Australia after his son was born with Usher syndrome. He will advise on Nacuity's oxidative stress therapies for retinitis pigmentosa and cataracts.GlobeNewswireNacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher SyndromeNacuity Pharmaceuticals announced that target enrollment of 48 patients has been reached in the SLO-RP Phase 1/2 trial of NPI-001 for retinitis pigmentosa associated with Usher syndrome. The trial is randomized, placebo-controlled, and patients will be followed for two years. Interim efficacy data are anticipated by year end 2023.BioSpaceNacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell KelleyNacuity Pharmaceuticals, Inc. announced the appointment of Dr. Russell Kelley to its board of directors. Dr. Kelley serves as managing director of the Retinal Degeneration Fund, a significant investor in the company and the venture arm of Foundation Fighting Blindness. This addition brings investment and scientific expertise to support Nacuity's clinical trials for retinal diseases.GlobeNewswireNacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001Nacuity Pharmaceuticals and Arctic Therapeutics have entered into an exclusive licensing agreement and strategic partnership to develop and commercialize NPI-001 for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA) in Iceland. The collaboration involves joint efforts on regulatory approval and development activities, with Nacuity granting Arctic exclusive rights for this specific indication. HCCAA is a rare, fatal genetic disease primarily affecting the Icelandic population for which there are currently no approved treatments.VC News DailyNacuity Pharmaceuticals Inks $16.5M Series BNacuity Pharmaceuticals, a clinical-stage biopharmaceutical company based in Fort Worth, Texas, announced the closing of a $16.5 million Series B financing round. The round was led by Foundation Fighting Blindness and its venture arm RD Fund, with participation from additional existing investors. The company is developing treatments for ocular diseases caused by oxidative stress, including retinitis pigmentosa, cataracts, and cystinosis, with three clinical programs currently ongoing.